Melanoma News and Research

Latest Melanoma News and Research

Heart transplant patients face increased risk for skin cancers

Many heart transplant patients develop multiple skin cancers, with increased risk for some skin cancers among patients with other cancers and with increasing age, according to a report in the December issue of Archives of Dermatology, one of the JAMA/Archives journals.

22 Dec 2009

ZymoGenetics restructures license and collaboration agreements on RECOTHROM

ZymoGenetics, Inc. today announced a restructuring of the U.S. co-promotion and ex-U.S. license and collaboration agreements with Bayer Schering Pharma AG and Bayer HealthCare relating to RECOTHROM® Thrombin, topical (Recombinant).

21 Dec 2009

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.

21 Dec 2009

Phase 2 clinical study of STA-9090 in NSCLC initiated

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 2 clinical study of STA-9090 in non-small cell lung cancer (NSCLC).

18 Dec 2009

Typical smoker acquires one mutation for every 15 cigarettes and all cancers are caused by mutations

Research teams led by the Wellcome Trust Sanger Institute announce the first comprehensive analyses of cancer genomes.

17 Dec 2009

AAD's National Melanoma/Skin Cancer Screening Program reaches milestone

One person dies from melanoma, the deadliest form of skin cancer, almost every hour. Yet melanoma is often successfully treated, if caught early. That's why thousands of dermatologists across the country offer free skin cancer screenings in their communities through the American Academy of Dermatology's (AAD) National Melanoma/Skin Cancer Screening Program.

17 Dec 2009

JCTM established to advance new research toward clinical applications

The California Institute of Technology (Caltech) and the University of California, Los Angeles (UCLA) have announced the establishment of the Joint Center for Translational Medicine (JCTM), which will advance experimental research into clinical applications, including the diagnosis and therapy of diseases such as cancer.

17 Dec 2009

GlobalHealth Education & Training service established to meet growing demand in healthcare

Long-time healthcare education business owner, Deborah Kann Schwarzberg, has established GlobalHealth Education & Training®, a corporate training and degree-granting educational service. GlobalHealth was formed to respond to the growing demand for trained employees and management within the healthcare and ancillary industries to enhance their formal education and attain advanced degrees online.

16 Dec 2009

BioAlliance Pharma SA to enter Phase II clinical trial for clonidine Lauriad and Phase I clinical trial for AMEP

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces the approval from the French Drug Agency (AFFSSaPS) to enter Phase II clinical trial for clonidine Lauriad® in radiotherapy and chemotherapy-induced oral mucositis and the approval from Danish and Slovene Agencies to enter Phase I clinical trial for AMEPTM in invasive melanoma.

15 Dec 2009

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

Researchers at the Los Angeles Biomedical Research Institute (LA BioMed) expect to receive more than $4.5 million in grants from the American Recovery and Reinvestment Act (Recovery Act.), including nearly $1 million from the highly competitive Challenge Grant program for a study that seeks to reduce the number of children who die from Sudden Infant Death Syndrome, it was announced today.

15 Dec 2009

Oncolytics Biotech develops REOLYSIN for patients affected by hard-to-treat cancers

A novel class of cancer therapies called live biologics is offering new hope for patients affected by hard-to-treat cancers, according to two different studies testing the therapies in patients with sarcomas and head and neck cancers.

14 Dec 2009

Pfizer announces results from studies evaluating neratinib

Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Data from Phase 3 clinical evaluation of Lymphoseek presented

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that researchers who participated in the breast cancer arm of a Phase 3 clinical evaluation of Lymphoseek® presented data from their clinical experience at the International San Antonio Breast Cancer Symposium.

14 Dec 2009

Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics

Celldex Therapeutics, Inc. today announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers.

13 Dec 2009

Pfizer announces IES analysis of Aromasin in breast cancer recurrence

Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.

11 Dec 2009

Initiation of multi-national Phase III study of Stimuvax announced

Merck KGaA, Darmstadt, Germany, today announced the initiation of its multi-national Phase III study of the investigational therapeutic cancer vaccine Stimuvax® (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC).

11 Dec 2009

Eli Lilly provides financial guidance for 2010

At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.

10 Dec 2009

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13.

9 Dec 2009

Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, has completed a Phase 3 clinical trial of Lymphoseek® (NEO3-05) with positive results.

9 Dec 2009

Scientists identify new potential drug for treating acute myeloid leukaemia

EUREKA project E! 3172 NKSTIM has produced a new potential drug to stimulate cancer patients' own 'natural killer' cells to attack and eliminate cancer cells; currently undergoing clinical testing in patients with leukaemia or myeloma.

8 Dec 2009